Increases in apoptosis/cell death were also observed for combination treatment of primary AML samples carrying FLT3/ITD or FLT3/KD mutations (Fig. 2b and Supplementary Fig S6). The gene discussed is FLT3; the disease is acute myeloid leukemia.